In Vivo Visual Screen for Dopaminergic Rab ↔ LRRK2-G2019S Interactions in Drosophila Discriminates Rab10 from Rab3
Author(s) -
Stavroula Petridi,
C. A. Middleton,
Chris Ugbode,
Alison Fellgett,
Laura Covill,
Christopher Elliott
Publication year - 2020
Publication title -
g3 genes genomes genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.468
H-Index - 66
ISSN - 2160-1836
DOI - 10.1534/g3.120.401289
Subject(s) - rab , lrrk2 , neurodegeneration , dopaminergic , biology , neuroscience , in vivo , gtpase , microbiology and biotechnology , genetics , pathology , medicine , mutation , disease , dopamine , gene
LRRK2 mutations cause Parkinson's, but the molecular link from increased kinase activity to pathological neurodegeneration remains undetermined. Previous in vitro assays indicate that LRRK2 substrates include at least 8 Rab GTPases. We have now examined this hypothesis in vivo in a functional, electroretinogram screen, expressing each Rab with/without LRRK2-G2019S in selected Drosophila dopaminergic neurons. Our screen discriminated Rab10 from Rab3. The strongest Rab/LRRK2-G2019S interaction is with Rab10; the weakest with Rab3. Rab10 is expressed in a different set of dopaminergic neurons from Rab3. Thus, anatomical and physiological patterns of Rab10 are related. We conclude that Rab10 is a valid substrate of LRRK2 in dopaminergic neurons in vivo We propose that variations in Rab expression contribute to differences in the rate of neurodegeneration recorded in different dopaminergic nuclei in Parkinson's.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom